Development of vaccines against self-antigens: The p53 paradigm

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 2, 2003, Pages 169-173

  Chada, Sunil ^a   Mhashilkar, Abner ^a   Roth, Jack A ^b   Gabrilovich, Dmitry ^c  

^a Introgen Therapeutics Inc   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Antibodies; Antigen presentation; Cancer; CTL; Dendritic cell; Gene delivery; Gene therapy; HER 2 neu; Immune; Immunotherapy; Oncogene; P53; Ras; TERT; Tumor suppressor; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; ANTIGEN; PROTEIN P53; TUMOR ANTIGEN; VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARCINOGENESIS; DENDRITIC CELL; DRUG RESEARCH; HUMAN; IMMUNE SYSTEM; MALIGNANT TRANSFORMATION; ONCOLOGY; PROTEIN EXPRESSION; REVIEW; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; DENDRITIC CELLS; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037344669     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, Troychak MJ, Boynton AL, Murphy GP: GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate (1999) 39:291-297.
2. Lodge P, Jones LA, Bader RA, Murphy GP, Salgaller ML: Dendritic cellbased immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial. Cancer Res (2000) 60:829-833.
3. Renkvist N, Castelli C, Robbins PF, Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother (2001) 50:3-15. A comprehensive overview of TAAs.
4. Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC: Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: Relationship with apoptosis and proliferation. Prostate (1998) 37:223-229.
5. Liebermann DA: Normal development, oncogenesis and programmed cell death. Oncogene (1998) 17:1189-1194.
6. Vogelstein B, Kinzler KW: p53 Function and dysfunction. Cell (1992) 70:523-526.
7. Soussi T: p53 Antibodies in the sera of patients with various types of cancer: A review. Cancer Res (2000) 60:1777-1788. A superb and comprehensive review of p53-reactive antibodies in cancer patients.
8. Takahashi M, Chen W, Byrd DR, Disis ML, Huseby ES, Qin H, McCahill L, Nelson H, Shimada H, Okuno K et al: Antibody to Ras proteins in patients with colon cancer. Clin Cancer Res (1995) 10:1071-1077.
9. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P et al: Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst (1996) 88:1228-1233. A comprehensive analysis of p53-reactivities in patient sera.
10. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E: Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med (2000) 6:1011-1017.
11. Hunger RE, Brand CU, Streit M, Eriksen JA, Gjertsen MK, Saeterdal I, Braathen LR, Gaudernack G: Successful induction of immune responses against mutant Ras In melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp Dermatol (2001) 10:161-167.
12. Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, Schlom J: Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol (1997) 182:137-151.
13. Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta (1994) 1198:165-184.
14. Knutson KL, Schiffman K, Cheever MA, Disis ML: Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res (2002) 8:1014-1018.
15. Soddu S, Sacchi A: p53: Prospects for cancer gene therapy. Cytokines Cell Mol Ther (1998) 4:177-185.
16. Vousden KH: p53: Death star. Cell (2000) 103:691-694.
17. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature (1991) 351:453-456.
18. Hartmann A, Blaszyk H, Cunningham JS, McGovern RM, Schroeder JS, Helander SD, Pittelkow MR, Sommer SS, Kovach JS: Overexpression and mutations of p53 in metastatic malignant melanomas. Int J Cancer (1996) 67:313-317.
19. Hartmann A, Blaszyk H, Saitoh S, Tsushima K, Tamura Y, Cunningham JM, McGovern RM, Schroeder JJ, Sommer SS, Kovach JS: High frequency of p53 gene mutations in primary breast cancers in Japanese women, a low-incidence population. Br J Cancer (1996) 73:896-901.
20. IARC TP53 Mutation Database. International Agency for Research on Cancer, Lyon, France. http://www.iarc.fr/P53
21. Soussl p53 database. Institut Curie/Université Pierre & Marie Curie, Paris, France. http://p53.curie.fr/
22. Zeimet AG, Riha K, Berger J, Widschwendter M, Hermann M, Daxenbichler G, Marth C: New insights into p53 regulation and gene therapy for cancer. Biochem Pharmacol (2000) 60:1153-1163.
23. Swisher SG, Roth JA, Komaki R, Gu J, Hicks M, Ro JY, Hong WK, Ahrar K, Atkinson N, Correa AM et al: Induction of p53-regulated genes and tumor regression in lung cancer patients following intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 9:93-101.
24. Gabrilovich DL: Dendritic cell vaccines for cancer treatment. Curr Opin Mol Ther (2002) 4:452-458. An excellent review of DC biology, maturation and antigen loading.
25. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A: Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going? J Natl Cancer Inst (2002) 94:805-818. A detailed review of peptide-based tumor vaccines.
26. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ: Detection of transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA (1979) 76:2420-2424.
27. Pfizenmaier K, Pan SH, Knowles BB: Preferential H-2 association in cytotoxic T cell responses to SV40 tumor-associated specific antigens. J Immunol (1980) 124(4):1888-1891.
28. Melief CJ, Kast WM: T-cell immunotherapy of cancer. Res Immunol (1991) 142:425-429.The first discussion of obligate tumor antigens in immunotherapy.
29. Peace DJ, Chen W, Nelson H, Cheever MA: T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol (1991) 146:2059-2065.
30. He L, Feng H, Raymond A, Kreeger M, Zeng Y, Graner M, Whitesell L, Katsanis E: Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol Immunother (2001) 50:31-40.
31. Houbiers JG, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJ, Brand A, Momburg F, Kast WM, Melief CJ: In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol (1993) 23:2072-2077. An early demonstration of p53 as target antigen.
32. Bertholet S, Iggo R, Corradin G: Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides. Eur J Immunol (1997) 27:798-801.
33. Ciernik IF, Berzofsky JA, Carbone DP: Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes. Clin Cancer Res (1996) 2:877-882.
34. Gabrilovich DL, Ciernik IF, Carbone DP: Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumorbearing hosts. Cell Immunol (1996) 170:101-110.
35. Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, Berzofsky JA: A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res (1993) 53:3257-3261.
36. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med (1996) 183:1357-1365.
37. Hurpin C, Rotarioa C, Bisceglia H, Chevalier M, Tartaglia J, Erdile L: The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. Vaccine (1998) 16:208-215.
38. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ: p53 As a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA (1996) 93:4781-4786.
39. Nikitina EY, Clark JI, Van Beynen J, Chada S, Virmani AK, Carbone DP, Gabrilovich DI: Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res (2001) 7:127-135. This article demonstrated that patient immune cells could be effectively stimulated by Ad-p53-treated DCs.
40. Nikitina EY, Chada S, Muro-Cacho C, Fang B, Zhang R, Roth JA, Gabrilovich DI: An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Therapy (2002) 9:345-352. This paper demonstrated that tolerance to self-protein could be overcome without adverse effects.